- Tytuł:
- Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial
- Autorzy:
- Źródło:
- In The Lancet Infectious Diseases March 2022 22(3):329-340
Czasopismo naukowe